MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ
3.160
+0.080
+2.60%
After Hours: 3.260 +0.1 +3.16% 18:48 01/02 EST
OPEN
3.190
PREV CLOSE
3.080
HIGH
3.320
LOW
3.160
VOLUME
3.05K
TURNOVER
--
52 WEEK HIGH
7.00
52 WEEK LOW
2.521
MARKET CAP
57.28M
P/E (TTM)
-4.2206
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATHE last week (1222-1226)?
Weekly Report · 12/29/2025 09:05
Weekly Report: what happened at ATHE last week (1215-1219)?
Weekly Report · 12/22/2025 09:05
Alterity Therapeutics Initiated at Speculative Buy by Canaccord Genuity
Dow Jones · 12/17/2025 13:03
Alterity Therapeutics initiated with a Speculative Buy at Canaccord
TipRanks · 12/17/2025 12:20
Canaccord Genuity Sticks to Their Buy Rating for Alterity Therapeutics (PRNAF)
TipRanks · 12/17/2025 06:05
*Alterity Therapeutics Started With A$0.016/Share Target Price by Canaccord Genuity>ATH.AU
Dow Jones · 12/17/2025 01:01
*Alterity Therapeutics Started at Spec Buy by Canaccord Genuity >ATH.AU
Dow Jones · 12/17/2025 01:01
Weekly Report: what happened at ATHE last week (1208-1212)?
Weekly Report · 12/15/2025 09:05
More
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ: ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.